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(Requests for offprints should be addressed to L Bonaccorsi; Email: l.bonaccorsi@dfc.unifi.it)AbstractAlthough androgens and the androgen receptor (AR) are involved in tumorigenesis of prostate cancer (PC) in initial
phases, less clear is the role played in advanced androgen-independent (AI) stages of the disease. Several recent
reports indicated that re-expression of AR in PC-derived cell lines determines a less aggressive phenotype of the cells.
We have previously demonstrated that re-expression of AR decreases the invasion ability of PC3 cells in vitro by affecting
signalling and internalization processes of epidermal growth factor receptor (EGFR). Here, we show that reduced EGFR
internalization is also a characteristic of AR positive PC cell lines LNCaP and 22Rv1. Reduced internalization in PC3-AR
cells is associated to a defective interaction between the EGFR and two adaptor proteins which mediate the endocytotic
process, Grb2 and c-Cbl. As a consequence of such reduced interaction, ubiquitination of the receptor, which is mainly
mediated by c-Cbl, is also altered. In addition, we show that internalized EGFR co-localizes with early endosome antigen-
1, a marker of clathrin-mediated endocytosis, in PC3-Neo cells but not in AR positive cell lines. Conversely, EGFR
maintains co-localization with caveolin-1 after EGF stimulation in PC3-AR cells. These data suggest that expression of
AR affects clathrin-mediated endocytosis pathway of EGFR, which, according to recent findings, plays an essential role in
the completeness of signalling of the receptor. Taken together, these data emphasize the role of AR in the regulation of
EGFR endocytotic trafficking and active signalling in PC cells. In view of the role of EGFR signalling in invasion of
carcinoma cells, our data may explain the lower invasive phenotype observed in AR-positive cell lines.Journal of Molecular Endocrinology (2007) 38, 51–66Introduction
Trafficking of growth factor receptors is an important
process in the pathogenesis of cancer (Polo et al. 2004).
Although until a few years ago, ligand-induced receptor
internalization was considered a mechanism exclusively
devoted to down-regulate growth factor signalling, it is
now evident that signalling of tyrosine kinase receptors
proceeds at endosomal level (Sorkin 2001) and recruit-
ment of certain adaptor proteins occurs after internal-
ization (Burke et al. 2001) implicating endocytosis in the
propagation of intracellular signals, assuring compart-
mentalization and transporting signalling complexes to
specific subcellular locations (McPherson et al. 2001). As
an example, normal endocytotic trafficking of activated
epidermal growth factor receptor (EGFR) is required to
achieve full activation of epidermal growth factor (EGF)
signalling (Vieira et al. 1996). In addition, it has been
recently shown that Huntingtin-interacting protein 1
causes transformation of cells by prolonging activation
and signalling of growth factor receptors after endocy-
tosis (Hyun & Ross 2004). EGFR endocytosis may
proceed through two different routes, namedJournal of Molecular Endocrinology (2007) 38, 51–66
0952–5041/07/038–051 q 2007 Society for Endocrinology Printed in Great Britainrespectively clathrin-dependent and -independent
(also known as lipid raft-dependent). While the
clathrin-dependent pathway leads to signalling, the
clathrin-independent leads mainly to lysosomal
degradation (Aguilar & Wendland 2005).
TheEGFRand its ligand, theEGF, play a key role in the
pathogenesis of different tumours, including prostate
cancer (PC; Russell et al. 1998) where both EGF and
EGFR are often up-regulated in particular in advanced
stages (Di Lorenzo et al. 2002). In addition to
proliferation, EGFRplays a key role in invasion of cancer
cells (Wells et al. 2002) participating, in association with
specific integrins, in the formation of the plasma
membrane structures (lamellipodia) that mediate
migration through the basal membrane (Rabinovitz
et al. 2001). Recently, it has been shown that increased
EGFR expression enhances tumour invasiveness of
mammary adenocarcinomas by increasing cell motility
in vivo without affecting the growth of the tumour
(Xue et al. 2006), pointing out the key role exertedby the
EGF/EGFR system in invasion andmetastasis. Inhibition
of EGFR with monoclonal antibodies or with tyrosine
kinase inhibitors inhibits either growth and invasion ofDOI: 10.1677/jme.1.02155
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in vitro (Bonaccorsi et al. 2004b, Festuccia et al. 2005).
We previously demonstrated that re-expression of AR
in the androgen-independent (AI) prostate cancer cell
line PC3 by transfection (PC3-AR cells) determined a
decrease in their ability to invade Matrigel in response
to EGF (Bonaccorsi et al. 2000). This effect is
determined either by a decrease in expression levels
of the integrin a6b4 (Bonaccorsi et al. 2000) or by an
alteration of EGF-activated signalling with respect to
control cells (Bonaccorsi et al. 2004a). In particular,
EGFR autotransphosphorylation, recruitment of phos-
phatidyl inositol-3-kinase (PI3K), PI3K/AKT activation
and internalization of the receptor in response to the
ligand were all reduced in PC3-AR cells and were
further reduced by treatment with an androgen
(Bonaccorsi et al. 2004a). We also demonstrated that
EGFRs co-localize and -immunoprecipitate with AR in
PC3-AR cells and suggested that such interaction
interferes with activation of EGFR (Bonaccorsi et al.
2004a, 2006). Overall, these results indicate that the
higher invasive phenotype displayed by AI PC cell lines
with respect to AD ones (Baldi et al. 2003) might be in
part explained by a different sensitivity to EGF.
The present study was undertaken to investigate the
possible alterations of EGFR signalling leading to
deregulated endocytosis of the receptor in AR-positive
PC cell lines. We show that phosphorylation of specific
tyrosines of COOH-terminal domain, interaction with
the specific adaptor proteins Grb-2 and c-Cbl, ligand-
mediated ubiquitination of EGFR and interaction with
early endosome antigen-1 (a marker of clathrin-
dependent endocytosis) are all reduced in PC3-AR
with respect to control cells.Materials and methods
Antibodies and chemicals
Rabbit polyclonal anti-EGF receptor antibody was
obtained from Cell Signaling Technology Inc. (Dan-
vers, MA, USA), rabbit polyclonal anti-phospho-EGF
receptor (Tyr845), (Tyr992), (Tyr1045), (Tyr1148),
(Tyr1168), (Tyr1173), (Tyr1086) antibodies, rabbit
polyclonal anti-phospho-EGF receptor (ser1046/1047)
antibody and rabbit polyclonal anti-GRB2 antibody was
obtained from Cell Signaling Technology Inc. Mouse
mAb Ab2 (anti EGFR) and mouse mAb Ab1 (anti
EGFR) were from Oncogene (Cambridge, UK). Mouse
monoclonal EGF Receptor Ab12 was from NeoMarkers,
Lab Vision Corporation (CA, USA). Mouse anti-human
mAb anti-c-Cbl was from BD Biosciences (Pharmingen
San Diego, CA, USA). Rabbit polyclonal anti-early
endosome marker (EEA-1) antibody was from Abcam
Ltd (Cambridge, UK). Antiphosphotyrosine PY20Journal of Molecular Endocrinology (2007) 38, 51–66antibody was obtained from ICN (Costa Mesa, CA,
USA), antiphosphotyrosine PY99 antibody was pur-
chased from Santa Cruz (Santa Cruz, CA, USA). Mouse
monoclonal anti EGFR (1005) was from Santa Cruz
Biotechnology. Mouse monoclonal antibody against
ubiquitin was from Covance Research Products Inc
(Denver, PA, USA). Monoclonal anti-ubiquitin antibody
was provided from Medical & Biological Laboratories
Co. (Nagoya, Japan). Rabbit anti-ubiquitin antibody was
from SIGMA Chemical Co. Anti-caveolin antibody was
obtained from BD Farmingen (San Diego, CA, USA).
Recombinant human EGF was obtained from Pepro
Tech EC (London, UK). Fluorescein-conjugated EGF
and Alexa Flour 488 goat anti mouse IgG were obtained
from Molecular Probes Inc, Invitrogen. Anti rabbit IgG
(goat) Texas Red conjugate was from Calbiochem (CA,
USA). The antibiotic Geneticin (G418) was obtained
from Calbiochem. Protease inhibitor cocktail and other
not specified reagents were from SIGMA Chemical Co.
R1881 was from NEN Perkin–Elmer Life and Analytical
Sciences (MA, USA).Cell lines
Androgen receptor (AR)-negative PC3 and AR-positive
LNCaP PC cell lines were obtained from American
Tissue Culture Collection (Bethesda, MD, USA).
AR-positive 22Rv1 PC cells were generously provided
by Prof. Culig (Innsbruck Medical University, Austria).Cell culture and transfection
PC3 cells were maintained in HAM-F12 Coon supple-
mented with 10% FBS, 1% penicillin/streptomycin and
1% glutamine. Before stimulation with androgens, cells
were kept for 24 h in serum- and phenol red-free
medium. PC3 cells were transfected with human full
length androgen receptor construct (p5HbhAR) or
vector alone (PC3-NEO cells) by electroporation and
selected in the presence of 0.5 mg/ml geneticin (G418)
as described previously (Bonaccorsi et al. 2000). To
obtain stable colonies, individual clones were isolated
by limiting dilution and tested for the presence of the
AR both by northern and western analysis. Two
independent clones of PC3-AR transfected cells (# 6
and #13) were used in this study. The growth
characteristics in response to androgens of these two
clones have been described previously (Bonaccorsi et al.
2000). Both clones exhibit similar growth charac-
teristics although they grow slowly with respect to
parental or Mock-transfected PC3-Neo cells (basal
thymidine incorporation (meanGS.E.M. cpm/well/
4 h): PC3-NeoZ12572G4939; clone#6Z2355G1384*;
clone #13Z5378G2829†, *P!0.005 and †P!0.05 vs
PC3-Neo). LNCaP cells were cultured in RPMI mediumwww.endocrinology-journals.org
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mycin and 1% glutamine. The 22Rv1 cells were grown
in MCDB medium supplemented with 10% FBS, 1%
penicillin/streptomycin and 1% glutamine.Internalization assay by flow cytometry analysis
Cell surface EGFR expression was evaluated by flow
cytometry performed as described (Bonaccorsi et al.
2004a). Cells were grown on a Petri dish until
confluence, washed with PBS, detached with 0.1%
trypsin–EDTA and resuspended in PBS with 1 mM
CaCl2 and 1 mMMgCl2 that was supplemented with 4%
FBS. After the indicated treatments, cells were
incubated 30 min at 4 8C with the monoclonal anti-
EGFR antibody Ab1 or non-specific IgG as control,
washed twice with PBS and further incubated with
FITC-conjugated goat anti-mouse secondary antibody
(1:200) for 30 min. After washing twice, cells were fixed
with 3% paraformaldehyde in PBS at room temperature
for 15 min and washed twice. FITC green fluorescence
was detected at 515–555 nm using a FL-1 detector of a
FACScan flow cytometer (Becton Dickinson, Mountain
View, CA, USA) equipped with 15 mW argon–ion laser
for excitation. Debris were gated out by establishing a
region around the population of interest on the
Forward Scatter versus Side Scatter dot plot. For each
sample, 10 000 events in the region of interest were
recorded at a flow rate of 200–300 cells/s. Data were
processed with analysis software LYSYS II (Becton
Dickinson) and are expressed as median value of
EGFR expressing cells of the fluorescence histograms
normalized to the corresponding negative control
obtained by omitting the primary antibody.Immunoprecipitation and western blot analysis
Protein extraction and western blot analysis were
performed as previously described (Bonaccorsi et al.
2000). Immunoprecipitation was performed as pre-
viously described (Bonaccorsi et al. 1997) with few
modifications. Briefly, cells were scraped in PBS
supplemented with 1mM Na3VO4, centrifuged and
resuspended in lysis buffer (20 mM Tris, pH 7.4;
150 mM NaCl; 0.5% NP-40; 0.2% Triton-X; 1 mM
Na3VO4 and 1 mM PMSF). After protein measurement,
aliquots of cell lysates containing equal amount of
proteins (1000 mg) were incubated for 1 h at 4 8C with
30 ml of Protein A (or Protein G)-Sepharose for
preclearing. Precleared lysates were then incubated
for 1 h using 5 mg specific antibodies on ice followed by
overnight incubation at 4 8C with 30 ml Protein A (or
Protein G)-Sepharose. The immunobeads were washed
thrice in lysis buffer and then resuspended in 10 ml of
2! reducing sample buffer, boiled and loaded onto 8%www.endocrinology-journals.orgpolyacrylamide–bisacrylamide gels. After SDS-PAGE,
proteins were transferred to nitrocellulose membranes.
The membranes were blocked overnight at 4 8C in 5%
BSA–TTBS (0.1% Tween 20, 20 mM Tris and 150 mM
NaCl). After washing in TTBS, the membranes were
incubated 2 h at room temperature or overnight at 4 8C
with the different primary antibodies followed by
incubation with peroxidase-conjugated relative second-
ary antibodies. Finally, probed proteins were revealed
by enhanced-chemiluminescence system (BM, Roche).
After the first blotting with peroxidase-conjugated
secondary antibodies, nitrocellulose membranes were
stripped at 50 8C for 30 min in stripping buffer
(100 mM 2b-mercaptoethanol; 2% SDS and 62.5 mM
Tris–HCl, pH 6.7) and re-probed with specific primary
antibodies.Confocal microscopy analysis
Immunofluorescence was performed as described
previously (Bonaccorsi et al. 2004a). Briefly, cells were
plated (1!106 cells) on glass coverslips and allowed to
adhere in a humidified atmosphere with 5% CO2 at
37 8C. The cells were then stimulated with EGF (10 ng/
ml for 15 min) and subsequently fixed with 2%
paraformaldehyde in PBS. Cells were permeabilized
15 min at RT with 0.1% Triton-X in PBS. After fixation,
the cells were rinsed in PBS and incubated in a blocking
solution containing 1% BSA and 5% goat serum in PBS
for 30 min. Primary antibodies in blocking solution
were added in combination to the fixed cells and
incubated at 4 8C for 30 min. After washing in PBS, the
immunoreactivity was revealed using Alexa Fluor 488
goat anti-mouse IgG, FITC-conjugated or Texas Red-
conjugated anti-mouse, or anti-rabbit secondary
antibodies (minimal inter-species cross reaction) in
blocking buffer (1:50) used separately or in com-
bination to stain the cells for 30 min. Negative controls
were performed by substituting the primary antibodies
with the blocking buffer. The immunostained cells were
rinsed with PBS and mounted in a mixture (8:2) of
glycerol and PBS (pH 8.5). Internalization of fluor-
escein-conjugated EGF was performed following the
protocol described by Sigismund et al (2005). Briefly,
FITC-conjugated EGF (1 mg/ml) was added for 1 h at
0 8C followed by wash and shift at 37 8C for 15 min to
allow internalization. After fixation, the samples were
analysed under a laser scanning confocal microscope
(Bio-Rad MRC 1024 ES, Hercules CA) equipped with a
krypton/argon laser source 15 nm. A series of optical
sections (512!512 pixels) were taken through the
depth of the cells with a thickness of 1 mM at intervals of
0.8 mM by using a Nikon 60X 1.4 oil immersion
objective. Each section was signal averaged during
acquisition to improve image quality, using the Kalman
averaging option (5 scan), and the entire series wasJournal of Molecular Endocrinology (2007) 38, 51–66
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tion. To reduce bleed-through effects, dual channel
scanning of red and green signals were recorded
separately and saved in two different files.Statistical analysis
Statistical analysis was performed with ANOVA and
Student’s t-test for unpaired and, when applicable,
paired data.Results
EGFR internalization is altered in androgen-sensitive
PC cells
In Fig. 1A western analysis of EGFR and AR expression
in the four cell lines is shown. The 22Rv1 cells express
the highest level of EGFR with respect to the other cell
lines, whereas EGFR expression is similar in PC3-Neo
and PC3-AR cells as previously demonstrated (Bonac-
corsi et al. 2004a). In agreement with previous
published data (Mendoza et al. 2002, Oosterhoff et al.
2005), LNCaP cells express lower levels of EGFR when
compared with PC3 cells. Concerning AR expression, as
expected, LNCaP cells are characterized by high levels
of the receptor when compared with PC3-AR (clone 6)
and 22RV1 cells (Fig. 1A).
We have shown previously that EGFR internalization
is altered in PC3-AR cells with respect to the parent cell
line transfected only with the vector (Bonaccorsi et al.
2004a). Here, we confirm such alteration by confocal
immunofluorescence. EGFR was visualized in the
absence (C) and presence of EGF (10 ng/ml, 10 min)
by staining with anti-EGFR antibody. Before stimu-
lation, EGFR was clearly localized and homogenously
distributed to the membrane in all the cell lines studied
(Fig. 1B and C; C micrographs), as denoted by almost
complete absence of vesicular structures. After 10 min
stimulation with EGF, vesicular structures containing
EGFR were present at high density in PC3-Neo cells
(Fig. 1B, EGF), whereas only a few vesicles were present
in the cytoplasm of PC3-AR (Fig. 1B, EGF), LNCaP and
22Rv1 (Fig. 1C, EGF) cells. These results were
confirmed by the use of FITC-labelled EGF (1 mg/ml)
to stimulate the cells in PC3-Neo and PC3-AR cells. As
shown in Fig. 1B (lower panels, EGF-FITC), the probe
localized in discrete vesicles in PC3-Neo cells, whereas
fewer vesicles were observed in PC3-AR. Following EGF
treatment, PC3-Neo cells appear rounder with respect
to control. It is possible that such behaviour is due to
the fact that cells are induced to proliferate and to
migrate by the growth factor. Normalized median value
of EGFR before and after EGF stimulation for 10 min in
the four cell lines, quantified by flow cytometry analysis,Journal of Molecular Endocrinology (2007) 38, 51–66is shown in Fig. 1D. As shown, a high amount of EGFR is
internalized in PC3-Neo cells but not in AR-positive cell
lines PC3-AR, LNCaP and 22RV1.
To evaluate whether AR needs to be activated in
order to affect EGFR internalization, we have used the
anti-androgen 5-hydroxyflutamide (HF). PC3-Neo and
PC3-AR cells were treated with EGF (10 ng/ml, 10 min)
in the presence or absence of HF (1 mM) and EGFR
internalization was evaluated by FACScan analysis. As
shown in Fig. 2, in PC3-Neo cells, EGFR is almost
completely internalized in EGF-treated with respect to
control, as demonstrated by the shift of the positive
peak to the left, but not in PC3-AR cells, where the shift
of the peak was absent. Treatment with HF is not able to
restore EGFR internalization in PC3-AR cells, indicating
that AR does not need to be activated in order to affect
the process. However, it appears that the treatment with
HF affects the basal surface expression of EGFR in both
cell lines (as demonstrated by the decrease of the
positive peaks in untreated cells). This effect appears to
be independent of the AR antagonist activity of HF as
obtained also in PC3-Neo cells which lack AR.Phosphorylation of tyrosine and serine residues at
regulatory COOH-terminal domain of EGFR in PC3-AR
and in PC3-Neo cells
We demonstrated previously that EGF-mediated total
tyrosine phosphorylation of EGFR is reduced in PC3-AR
cells when compared with control cells (Bonaccorsi
et al. 2004a). The EGFR autotransphosphorylation
occurs in several tyrosine residues. In particular, auto-
trans-phosphorylation in tyrosine residues 845, 992,
1045, 1068, 1086, 1148 and 1173 in the carboxy-
terminal region of the EGFR has been shown to play a
role in rapid internalization of the receptor and
recruitment of adaptor proteins (Helin & Beguinot
1991, Sorkin et al. 1992). To investigate which tyrosine
residues show reduced phosphorylation in PC3-AR
cells, we evaluated EGF-induced phosphorylation of
the above mentioned tyrosine residues with respect to
control. To this aim, we performed western blot analysis
of immunoprecipitated EGFR from PC3-AR and PC3-
Neo cells by using phospho-specific antibodies directed
against the phosphorylated Tyr residues. We found that,
with the exception of tyr 845 and 1068, where EGF
induces an increase of phosphorylation albeit much
lower with respect to that elicited in PC3-Neo cells
(Fig. 3A and D), the growth factor does not stimulate
phosphorylation in any of the other analyzed tyrosine
residues in PC3-AR cells, whereas it does so efficiently in
PC3-Neo (Fig. 3 A–G). As can be observed in Fig. 3B,
Y992 phosphorylation is high in basal conditions in
both cell lines. Although we do not have a clear
explanation for this finding, it has recently been shown
that Y992 is more phosphorylated than other sites inwww.endocrinology-journals.org
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Figure 1 EGFR internalization in different prostate cancer cell lines. Panel A. Expression of EGFR and AR in
the different PC cell lines used in the present study. Cell total lysates were obtained from cells maintained in
serum-free and phenol red-free conditions for 24 h. For EGFR expression, cell lysates were immunoprecipi-
tated with anti-EGFR Ab1 antibody, run onto SDS-PAGE, blotted and revealed first with a polyclonal anti-
EGFR antibody and, after stripping, against actin. For AR expression, total lysates were run onto SDS-PAGE,
blotted and revealed with a polyclonal anti-AR antibody. Panels B and C. Confocal immunofluorescence of
EGFR expression in basal conditions (C) and after 10 min treatment with EGF (10 ng/ml) in PC3-Neo and
PC3-AR cells (upper micrographs), LNCaP cells (Panel C, upper micrographs) and 22Rv1 cells (Panel C,
lower micrographs). After treatment, cells were fixed, permeabilized and stained with the monoclonal anti-
EGFR antibody (Ab1) (for details see Materials and methods) and analysis was performed by confocal
microscopy. In Panel B (lower micrographs) cells were treated with FITC-conjugated EGF (1 mg/ml) for 10 min
and then analyzed. Representative of at least three similar experiments. Panel D. EGFR internalization in the
four different cell lines has been analyzed by FACScan analysis (for details see Materials and methods).
Results are expressed as normalized median value of EGFR surface expression of three different
experiments. *P!0.05 compared with control (C) of PC3-Neo cells.
EGFR endocytosis in prostate cancer cell lines . L BONACCORSI and others 55EGFR in A431 cells and that it is maximally stimulated
by low concentrations of the agonist (Guo et al. 2003).
In our previous paper, we demonstrated that the
treatment with androgen reduces both tyrosine phos-
phorylation and internalization of EGFR further with
respect to control (Bonaccorsi et al. 2004a). We show
here that treatment with the synthetic androgen R1881www.endocrinology-journals.org(0.1 nM for 3 days) does not substantially modify EGFR
phosphorylation in the different tyrosine residues with
the exception of those where EGF induces an increase
(respectively Tyr 845 and 1068, Fig. 3A and D).
Therefore, we conclude that the previously observed
inhibitory effect on total phosphorylation (Bonaccorsi
et al. 2004a) occurs mainly at the level of these twoJournal of Molecular Endocrinology (2007) 38, 51–66
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wtyrosine sites. Altogether these results indicate that
reduced internalization in PC3-AR cells is associated
with lack of autotransphosphorylation in several
tyrosine residues.Recruitment of adaptor proteins Grb2 and c-Cbl and
ubiquitination of EGFR are altered in PC3-AR cells
Grb2 and c-Cbl are adaptor molecules that couple
EGFR to intracellular signalling and have been
demonstrated to play a key role during early stage
of internalization pathway of activated EGFR (Yamazaki
et al. 2002, Jiang & Sorkin 2003, Ravid et al. 2004). In
particular, c-Cbl mediates ubiquitination of EGFR and
phosphorylation of tyr1045 appears to be essential for
this function of the adaptor protein (Ravid et al. 2004).
On the other hand, c-Cbl can also bind to EGFR
through binding to Grb2 (Levkowitz et al. 1999), which,
in turn, binds to Tyr 1068 and Tyr 1086 of EGFR. In view
of the absent/reduced phosphorylation in response to
EGF in Tyr1045 (Fig. 3C), 1068 (Fig. 3D) and 1086
(Fig. 3E) in PC3-AR cells, we evaluated whether the
interaction of EGFR with Grb2 and c-Cbl was also
affected by immunoprecipitating EGFR and perform-
ing subsequent western analysis using anti-Grb2 and
anti-cCbl antibodies. As shown in Fig. 4A, association of
both Grb2 and c-Cbl with EGFR is strongly reduced in
PC3-AR cells when compared with the parental cells.
As mentioned above, EGFR–c-Cbl interaction med-
iates ubiquitination of the receptor. Indeed, EGFR
mutants in tyr1045, where interaction of c-Cbl through
this tyrosine residue is disrupted, do not ubiquitinate
(Ravid et al. 2004). Moreover, de Melker et al. (2004)
have reported evidence that EGFR is ubiquitinated
when c-Cbl binds directly to the activated receptor via
its phosphotyrosine binding domain but not when it
binds through an adaptor such as Grb2. In view of these
data, we evaluated EGFR ubiquitination following
exposure to EGF. To this aim, cell lysates were
immunoprecipitated with anti-ubiquitin antibodies
and western analysis was performed first with anti-
EGFR and, after stripping, with PY20 antibody. As
shown in Fig. 4B (upper panel), a fraction of EGFR
co-immunoprecipitates with ubiquitin in PC3-Neo cells
following EGF stimulation, whereas EGFR-ubiquitin
co-immunoprecipitation is almost absent in PC3-AR
cells. Indeed, only after long exposure of the
membrane, does a band corresponding to EGFR
become evident in PC3-AR cells (not shown). Moreover,
the fraction of ubiquitinated EGFR in PC3-Neo cells isFigure 2 Effect of the anti-androgen 5-hydroxyflutamide (HF) on EGF
panels) and PC3-AR (lower panels) cells were treated for 10 min with
internalization was evaluated by FACScan analysis (see Materials an
treated cells. Representative of two similar experiments.
ww.endocrinology-journals.orgtyrosine phosphorylated in response to EGF (Fig. 4B
middle panel). An unidentified ubiquitinated band at
85 kDa is found to be tyrosine phosphorylated at the
same level in both cell lines and was not modified by
EGF treatment (Fig. 4B lower panel), indicating equal
amount of ubiquitinated proteins after immunoprecipi-
tation. Similar results were obtained after immuno-
precipitation of EGFR and blotting with an anti-
ubiquitin antibody in the two cell lines (Fig. 4C). A
smeared band corresponding to ubiquitinated EGFR is
present in EGF (10 ng/ml, 10 min)-treated PC3-Neo
cells, whereas EGFR ubiquitination is much less evident
in EGF-treated PC3-AR cells.
It has previously been postulated that the
Ser1046/1047 and 1057/1142 are important in the
regulation of EGFR tyrosine autotransphosphorylation
by promoting an interaction between the cytoplasmic
tail and the kinase domain (Feinmesser et al. 1999).
Recent data have demonstrated that these residues are
required for ligand-induced ubiquitination, internali-
zation and degradation of the receptor, since EGFR
mutants in these serine residues do not autophos-
phorylate, ubiquitinate and internalize in response to
EGF (Oksvold et al. 2003). To establish whether
restoration of androgen sensitivity also affects EGF-
induced phosphorylation at Ser1046/1047, we per-
formed western analysis of immunoprecipitated EGFR
in PC3-AR and PC3-Neo cells using anti-EGFR
pSer1046/1047 antibody. As shown in Fig. 4D, serine
phosphorylation does not increase in response to EGF
in PC3-AR cells, whereas the two sites are phosphory-
lated in PC3-Neo. Overall, this result confirms reduced
EGF signalling in PC3-AR cells and postulates that
reduced ubiquitination and internalization of EGFR
might also be due to reduced phosphorylation in serine
residues 1046/1047.Clathrin-mediated endocytosis is altered in
AR-positive PC cell lines
It has been demonstrated that two pathways exist for
endocytosis of membrane receptors, one leading to
degradation and the other to signalling and recycling to
the surface (Le Roy & Wrana 2005). In particular, the
clathrin-dependent pathway of internalization mediates
recycling, while the clathrin-independent ends with
receptor degradation (Le Roy &Wrana 2005). Recently,
it has been shown that EGFR also may follow the two
different endocytotic routes (Aguilar & Wendland
2005). We reasoned that in PC3-AR cells, the reducedR internalization in PC3-Neo and PC3-AR cells. PC3-Neo (upper
EGF (10 ng/ml) in the presence or absence of HF (1 mM). EGFR
d methods for details). Left panels, control; right panels, EGF-
Journal of Molecular Endocrinology (2007) 38, 51–66
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interaction with Grb2 and c-Cbl adaptors may contrib-
ute to disrupt trafficking of EGFR leading to decreased
internalization through the clathrin-dependent
pathway. To investigate this possibility, we performed
confocal microscopy immunofluorescence analysis by
using antibodies against early endosome antigen-1
(EEA-1) to study EGFR localization in early endosomes
(typical of the clathrin-dependent pathway; Sigismund
et al. 2005). As shown in Fig. 5 (right panels and higher
magnification subpanel), a strong co-localization is
evident following stimulation with EGF (10 min) in
PC3-Neo cells but not in the AR-positive cell lines PC3-
AR, 22Rv1 and LNCaP. These data indicate that in PC3-
Neo cells, EGFR internalization occurs mainly through
the clathrin-dependent pathway which is altered by the
expression of a functional AR. The EEA-1 expression is
similar in the four cell lines, as demonstrated by western
blot analysis (Fig. 5, insert).
Evidence in the literature suggests that EGFR-
caveolin interaction leads to reduced activation of
EGFR signalling (Couet et al. 1997). Therefore, we
sought to investigate EGFR–caveolin-1 interaction in
PC3-Neo and PC3-AR cells by confocal immunofluor-
escence. As shown in Fig. 6 (left panels), EGFR–
caveolin-1 interaction (yellow staining) is low in basal
conditions (C) in both cell lines, in agreement with data
showing that only a small fraction of EGFR is associated
to caveolin-1 (Couet et al. 1997, Khan et al. 2006).
Following stimulation with EGF, EGFR is redistributed
into punctate vesicular compartments within PC3-Neo
cells and yellow staining is completely lost (Fig. 6, left
panel). Conversely, in PC3-AR cells EGFR remains
slightly associated with caveolin-1 even after treatment
with EGF. Right panels of Fig. 6 show a confocal section
of the sum of the sections shown on the right to
demonstrate surface localization of caveolin-1. Caveo-
lin-1 expression is similar in the two cell lines (Fig. 6,
insert). Overall, our data indicate that sustained EGFR–
caveolin-1 co-association may be a result of suppressed
EGFR activation in the presence of AR.
To assess whether reduced internalization of EGFR in
AR-positive cells at 10 min is due to a different kinetic in
the internalization process, we evaluated EGFR
internalization at 60 and 120 min in PC3-Neo, PC3-
AR, LNCaP and 22RV1 cells. As shown in Fig. 7, EGFR is
almost completely internalized in PC3-Neo cells at both
60 and 120 min (as demonstrated by the shift to the leftFigure 3 EGF-induced phosphorylation in different tyrosine residues
(C) with R1881 (R, 0.1 nM, 3 days) and then treated with EGF (E,
After the different treatments, cells were scraped from the plate an
monoclonal anti-EGFR antibody Ab1, SDS-PAGE and transfer to n
antibodies directed against the indicated tyrosine phosphorylated sit
with an anti-EGFR antibody (middle blots) and an anti-actin antibo
experiments for each anti-tyrosine antibody. IB, immunoblot.
www.endocrinology-journals.orgof the peak in response to EGF at both time points). In
PC3-AR cells, EGFR is internalized at both time points,
although the process appears to be slower with respect
to PC3-Neo cells, as the shift of the peak to the left in
response to EGF is less marked in particular at 60 min.
Similar results are obtained in LNCaP cells where EGFR
internalization appears to be slower with respect to PC3-
Neo cells. Conversely, EGFR internalization is complete
at 60 min in 22RV1 cells. Interestingly, in these cells,
EGFR is present mostly on the surface at 120 min
despite the continuous presence of the growth factor,
suggesting a different kinetic of internalization/
recycling.Discussion
Understanding the molecular mechanisms through
which growth factor receptors are internalized rep-
resents a major focus of cancer research, as mutations
or altered expression of endocytotic proteins have often
been detected in tumours (Di Fiore & Gill 1999). In
particular, it is vital to understand how signal transduc-
tion and endocytosis pathways regulate each other and
how the breakdown of this integrated regulation
contributes to cancer development. Understanding
such links may be of help in providing an intervention
for cancer therapy. Indeed, internalization of receptor
controls the duration, intensity and specificity of
signalling (Sorkin 2001). The present paper reports
strong evidence that internalization pathways of EGFR
are altered in the AR-positive PC cell models used in
this study (PC3-AR, LNCaP and 22Rv1). In particular,
we demonstrate here that reduced autotransphosphor-
ylation of the receptor in several tyrosine residues as
well as interaction with adaptor proteins which mediate
its sorting to early endosome vesicles and thus clathrin-
dependent pathway of endocytosis are compromised in
AR-positive PC cell lines. Since endosome-associated
signalling relevant for activation of many specific
cellular functions occurs when internalization of
EGFR is driven through the clathrin-dependent route
(Aguilar & Wendland 2005), and endosomal signalling
of EGFR is required for EGF-mediated cell survival
(Wang et al. 2002), our findings may give a possible
explanation of the lower tumorigenic and invasive
phenotype of AR-positive PC cell lines with respect to
AR-negative (Bonaccorsi et al. 2000, Cinar et al. 2001,in PC3-Neo and PC3-AR cells. Cells were pre-treated or not
10 ng/ml, 10 min) in the presence or absence of R1881 (ECR).
d lysated. After immunoprecipitation (IP) of EGFR with the
itrocellulose, the different membranes were blotted with
es (panels A–G). Membranes were then stripped and re-blotted
dy (lower blots). Representative of at least two similar
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Figure 4 EGFR interaction with Grb2 and c-Cbl, EGFR ubiquitination and ser1046/1047 phosphorylation in
PC3-Neo and PC3-AR cells. Cells were treated or not (C) with EGF (E, 10 ng/ml 10 min) and EGFR was
immunoprecipitated (IP) with anti-EGFR antibody (Ab1) (panels A, C and D) (for details see Materials and
methods) or anti-ubiquitin antibody (panel B). Western blot analysis was performed with the indicated
antibodies. Representative experiments out of two similar are shown IB, immunoblot.
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Figure 5 Confocal immunofluorescence of EGFR-EEA-1 interaction. Immunofluorescence of EEA-1 (red)
and EGFR (green) is shown in basal conditions (C) and after treatment with EGF (10 ng/ml, 10 min) in PC3-
Neo, PC3-AR, LNCaP and 22Rv1 cells. Cells were fixed, permeabilized and subjected to immuno-
fluorescence using an anti-EGFR monoclonal antibody (Ab1) followed by FITC-conjugated secondary
antibody and an anti-EEA-1 polyclonal antibody followed by Texas Red-conjugated secondary antibody.
Co-localization analysis was performed by confocal microscopy. For simplicity only the merge images are
shown. The yellow staining is indicative of co-localization of the two antigens. Representative of three
different experiments. The panel of EGF treatment in PC3-Neo cells has been magnified threefold to show
better the yellow staining of internal vesicular structures. The inset shows a higher magnification of the
boxed area. Total cell lysates, obtained as described for Fig. 1, were separated onto SDS-PAGE and, after
blotting, probed with the anti-EAA1 polyclonal antibody.
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et al. 2005). Inline with our data, it has recently been
shown that transfection of AI PC cell lines with the
endocytosis protein REPS2 results in inhibition of
EGFR internalization and decrease of related signallingFigure 6 Confocal immunofluorescence of EGFR-caveo
(red) and EGFR (green) is shown in basal conditions (C)
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yellow staining is indicative of co-localization of the two
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Journal of Molecular Endocrinology (2007) 38, 51–66(Oosterhoff et al. 2005). REPS2 is among the endocy-
tosis regulating proteins whose expression is down-
regulated in AI PC (Oosterhoff et al. 2005). Interest-
ingly, REPS2 is highly expressed in LNCaP cells and in
other AD cell lines (Oosterhoff et al. 2005) where EGFRlin-1 interaction. Immunofluorescence of caveolin 1
, and after treatment with EGF (10 ng/ml, 10 min) in
ilized and subjected to immunofluorescence using
ITC-conjugated secondary antibody and an anti-
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mplicity only the merge images are shown. The
antigens. Representative of three different
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Figure 7 Internalization of EGFR at 60 and 120 min in PC3-Neo, PC3-AR, LNCaP and 22 RV1 cells.
PC3-Neo, PC3-AR, LNCaP and 22RV1cells were treated with EGF (10 ng/ml) for the indicated times.
EGFR internalization was evaluated by FACScan analysis (see Materials and methods for details).
Left panels, control; right panels, EGF-treated cells. Representative of two similar experiments.
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(Oosterhoff et al. 2005; present study). Of interest, it has
recently been shown in a neuroblastoma cell line that
internalization of the tyrosine kinase receptor RET is
required for complete activation of downstream
signalling proteins mediating proliferation
(Richardson et al. 2006). Noteworthy, decreased EGFR
internalization was observed in all the three AR-positive
cell lines, despite the fact that AR is mutated in different
sites respectively in LNCaP (Gaddipati et al. 1994) and
in 22Rv1 cells (Tan et al. 1997). This result suggests that
the mutations of the two cell lines do not impair the
ability of AR to affect EGFR internalization. In addition,
EGFR internalization in AR-positive cell lines does not
appear to be altered, since, when evaluated at 60 min
after EGF treatment, internalization occurs in all the
three cell lines. Rather, it appears that the kinetic of
EGFR internalization is affected by the steroid receptor.
Another important point concerns the need for
activation of AR in affecting EGFR internalization.
Here, we show that incubation with 5-hydroxyflutamide
(HF) does not restore EGFR internalization in PC3-AR
cells, suggesting that the genomic pathway of activation
of AR is not required for such an effect. On the other
hand we have shown previously that AR interacts with
EGFR in PC3-AR and LNCaP cells (Bonaccorsi et al.
2004a). The lack of effect of HF further suggests that
the inhibitory effect of AR on EGFR signalling and
internalization (Bonaccorsi et al. 2004a and present
study) is due to an extragenomic effect of the receptor.
However, a genomic effect on EGFR internalization and
signalling cannot be excluded, since in our previous
paper (Bonaccorsi et al. 2004a) we have shown that
treatment with a synthetic androgen further reduces
the two processes.
As mentioned above, internalization of EGFR may
occur through at least two different pathways, a clathrin-
dependent and a clathrin-independent (or raft-
mediated) one (Aguilar & Wendland 2005). According
to several studies, key mediators of clathrin-mediated
endocytosis are c-Cbl, that binds to the receptor and
sustains its ubiquitination (de Melker et al. 2004, Stang
et al. 2004), andGrb2, thatmediates entry into coated pits
(Huang & Sorkin 2005), although both effectors have
been also demonstrated to play an active role in clathrin-
independent EGFR endocytosis (Sigismund et al. 2005).
Here, we demonstrate that EGFR interaction with both
Grb2 and c-Cbl is strongly reduced in PC3-AR cells and
thus we hypothesize that such reduced interaction is
responsible for reduced internalization. Rather, the
receptor appears to remain, at least in part, localized in
a caveolar compartment (Fig. 6), where it can be
maintained in an inactive state (Zhang et al. 2000).
Asmentioned above, inour previous study (Bonaccorsi
et al. 2004a), we have shown that the treatment with
androgens further reduces signalling and internalizationJournal of Molecular Endocrinology (2007) 38, 51–66of the EGFR. Here, analyzing the single phosphorylated
tyrosine residues in response to EGF in PC3-AR cells, we
found a small increase only in residues 845 and 1068,
whereas no increase was apparent in the other investi-
gated residues. Interestingly, treatment with the synthetic
androgen R1881 was able to decrease phosphorylation in
845 and 1068 tyrosine residues, indicating that the effect
of the androgen on invasive properties of the cells
(Bonaccorsi et al. 2000) and on EGFR internalization
(Bonaccorsi et al. 2004a) might also be due to reduced
signallingmediatedby these two sites.On theotherhand,
tyr1068 directly binds Grb2 and is involved in the early
steps of endocytosis (Chook et al. 1996, Johannessen et al.
2006) as discussed above. Recently, Mills et al (2005) have
demonstrated that Huntingtin interacting protein 1
(HIP1), a nucleocytoplasmic protein involved in the
early step of endocytosis (Hyun & Ross 2004), is
overexpressed during progression towards AI PC. This
protein has been shown to prolong activation and
signalling of EGFR after the internalization step of
endocytosis (Hyun & Ross 2004), further supporting an
intriguingroleofendocytoticpathways in theprogression
of PC (Oosterhoff et al. 2005).
Our data indicate that, in PC cells, the presence of the
AR may have a regulatory function on EGF-mediated
pathways by inhibiting EGFR activation. In PC, the role
of androgens and AR appear to be twofold. In initial
phases of the disease, AR and its ligand represent the
first hint for uncontrolled cell growth, as also recently
outlined by the identification of a chromosomal
rearrangement, resulting in the fusion of an AR
regulated gene (TMPRSS2) and ETS transcription
factor family members ERG and ETV1, that is expressed
at high frequency in PC (Tomlins et al. 2005). The fusion
results in androgen-induced overexpression of these
proto-oncogenes which are likely the cause of tumor-
igenesis. However, enhanced AR activity does not
appear, per se, to be sufficient to cause aggressive growth
and progression, as in vitro experiments indicate that
androgens also induce differentiation of PC cells
(Whitacre et al. 2002, Berger et al. 2004). In addition,
there is clinical evidence indicating that correctly
functioning AR during disease progression may main-
tain a more differentiated and less tumorigenic pheno-
type. Indeed, patients with AI PC displaying
amplification of the AR gene survive longer than
patients without amplification (Debes & Tindall 2004)
and a higher level of AR protein expression correlates
with a higher differentiation of tumours (Heinlein &
Chang 2004). Moreover, it has recently been demon-
strated that during PC progression from low grade to
high grade and metastatic PC, a selective down-
regulation of the AR-targeted genes that inhibit
proliferation, induce differentiation or mediate apop-
tosis occurs (Hendriksen et al. 2006). Altogether this
evidence supports the notion that a correct AR pathwaywww.endocrinology-journals.org
EGFR endocytosis in prostate cancer cell lines . L BONACCORSI and others 65maymaintain a more differentiated phenotype of PC, as
observed in vitro in androgen-positive PC cell lines
(Bonaccorsi et al. 2000, 2004a, Cinar et al. 2001, Davis
et al. 2003, Nightingale et al. 2003, Guerini et al. 2005,
Hatzoglou et al. 2005) both by regulating genes affecting
growth and invasion (Bonaccorsi et al. 2000, Hendriksen
et al. 2006) and by interfering with signal transduction of
EGF (Bonaccorsi et al. 2004a, Oosterhoff et al. 2005;
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